## Topical Collection

# The Safety and Immunogenicity of the Bivalent Omicron-Containing mRNA-1273.214 Booster Vaccine

### Message from the Collection Editors

A bivalent vaccine from Moderna based on omicron BA.1 was approved for use as a booster dose by the Medicines and Healthcare Products Regulatory Agency. Preliminary data indicated that the vaccine generates a strong immune response against the BA.4 and BA.5 subvariants, which are now dominant worldwide. This new proposal behaves in the same manner as a flu-like situation, where everyone must take their flu vaccine at the start of winter each year and the composition of the vaccine is regularly modified in accordance with circulating strains. The new vaccines are highly effective in preventing disease severity but not transmission. We are pleased to invite you to submit to this Topical Collection for all kinds of manuscripts, such as research articles, brief reports, and communications to promote the knowledge and discussion about COVID-19 vaccines, especially bivalent vaccines. The invited papers broadly cover the safety and immunogenicity of COVID-19 vaccines in normal healthy persons, persons with moderate immunocompromised status and persons with severe immunocompromised status.

### Collection Editors


Dr. Lalit Batra

1. Regional Biocontainment Lab (RBL), Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM), University of Louisville, Louisville, KY 40222, USA
2. Bioengineering Department, J.B. Speed School of Engineering, University of Louisville, Louisville, KY 40292, USA

Dr. Shailendra Kumar Verma

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA



**Vaccines**

**an Open Access Journal by MDPI**

**Impact Factor 3.4**
**CiteScore 9.9**
**Indexed in PubMed**

mdpi.com/si/146282

*Vaccines*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

# Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

# About the Journal

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

## Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

## Author Benefits

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

**Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI